SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

In a significant move to strengthen its financial position and support expansion efforts, XBP Europe Holdings, Inc. (NASDAQ: XBP), a leading pan-European integrator of bills, payments, and related solutions, announced a new comprehensive financing agreement with HSBC UK Bank plc. The announcement, made on June 27, 2024, from the company’s dual headquarters in London, United Kingdom, and Santa Monica, California, marks a pivotal step in XBP Europe’s strategy to drive digital transformation across its client base.

Key Details of the Financing Agreement

The new financing structure introduced by XBP Europe involves a total of $48 million in new facilities, designed to refinance existing debts and increase the company’s liquidity. The financing agreement comprises:

  • A $4 million Term Loan A facility.
  • An $11 million Term Loan B facility.
  • A $15 million multicurrency revolving credit facility.

These facilities come with a competitive interest rate of the applicable reference rate plus 3.25%, along with an accordion feature that could allow the company to access up to an additional $18 million under certain conditions. The Term Loans are set to mature four years post-completion, whereas the Revolving Credit Facility has a three-year term with an option for a one-year extension at HSBC’s discretion.

Strategic Implications

The CEO of XBP Europe, Andrej Jonovic, expressed enthusiasm about the new financial arrangement, highlighting its role in enhancing the company’s liquidity and supporting its growth trajectory, including potential inorganic growth opportunities. “The strategic financing transaction with incremental borrowing capacity greatly enhances our liquidity and supports our runway for growth,” stated Jonovic.

The funds from the Term Loan A and Term Loan B have been used to clear the company’s previous indebtedness under its UK subsidiary’s prior term loans and revolving credit facilities, efficiently managing to avoid any penalties during this transition. Meanwhile, the capital from the Revolving Credit Facility is earmarked for general corporate purposes.

Financial Performance and Market Response

The announcement of this financing agreement comes at a time when XBP Europe is experiencing substantial market activity. The company’s stock surged by 58.20% to close at $1.93 on the day of the announcement. However, in after-hours trading, the stock saw a slight dip of 6.74%, settling at $1.80.

This strategic financial maneuver is set to solidify XBP Europe’s position in the market, providing the necessary resources to pursue further growth and maintain its competitive edge in the rapidly evolving digital payments landscape. As the company continues to implement its growth strategies, industry watchers and investors will likely keep a close eye on its operational performance and market expansion efforts.

Source: https://finance.yahoo.com/news/xbp-europe-holdings-inc-completes-174500893.html